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Acute graft-versus-host disease (aGVHD) still remains the main cause of morbidity and mortality after
allogeneic stem cell transplantation. Moreover, patients who did not respond to ﬁrst-line treatment with
glucocorticosteroids have a very poor outcome. Some studies suggested that alemtuzumab (a humanized
monoclonal antibody against the CD52 antigen) might be effective for treatment of refractory aGVHD. Here
we report a single-center experience with alemtuzumab in refractory gastrointestinal aGVHD. From
September 2009 to April 2012 at the Grenoble medical university center, 24 patients who had presented a
refractory gastrointestinal aGVHD to corticosteroid, or after another immunosuppressive drug, were retro-
spectively analyzed. Most patients (n ¼ 19) presented stage 4 gastrointestinal aGVHD. Response to treatment
(either complete or partial) was observed in 15 patients (62.4%). The overall survival rate at 1 year for all
patients was 33.3% (95% conﬁdence interval [CI], 15.9% to 51.9%) and for responders, 53.3% (95% CI, 26.3% to
74.4%). Two patients died from infection, 5 patients from recurrent GVHD, and 1 from an uncontrolled post-
transplant lymphoproliferative disorder.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Bone marrow transplant is a widespread procedure for
treatment of hematologic malignancies like acute leukemia.
Worldwide, about 50,000 allogeneic hematopoietic stem cell
transplantations are performed each year [1]. Although some
progress has been made in acute graft-versus-host disease
(aGVHD) prophylaxis, its occurrence remains common, with
prevalence from 35% to 45% in recipients of fully matched
sibling donor grafts to 60% to 80% in recipients of 1-antigen
HLA-mismatched unrelated donor grafts [2,3]. aGVHD is
still the major cause of morbidity and mortality after stem
cell transplantation. Initial treatment usually includes high-
dose glucocorticosteroids, with a response rate of 30% to
70% [4-6]. The prognosis for patients who do not respond
remains poor [7]. Although a consensus exists for the ﬁrst-
line treatment of aGVHD, there is no consensus as to
second-line treatment, and the choice of the second immu-
nosuppressive agent depends on the experience of the
clinical team [8]. Several second-line treatments have been
tried in the past, such as antithymoglobulin, tacrolimus,
mycophenolate mofetil, antitumor necrosis factor, and anti-
interleukin 2 receptor, with response rates of around 30%
to 50% [9-14].
Alemtuzumab (a humanized monoclonal antibody
against the CD52 antigen) is an immunosuppressive drug
targeting the CD52 antigen expressed on T cells, B lympho-
cytes, monocytes, dendritic cells, macrophages, and eosino-
phils. All these immune cells can be involved in GVHD [15].dgment on page 1454.
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14.05.031Alemtuzumab is also used for the prevention of GVHD
[16,17], and some studies have already shown the efﬁciency
of alemtuzumab in steroid-refractory GVHD [18,19]. Here, we
investigated the effectiveness of alemtuzumab for refractory
gastrointestinal aGVHD in 24 patients.
METHODS
Patients
We identiﬁed all patients who had developed a gastrointestinal steroid-
refractory aGVHD or a gastrointestinal aGVHD resistant to another line of
immunosuppressive drug after corticosteroids and were treated by alemtu-
zumab at Grenoble University Hospital (France) between September 1, 2009
and April 1, 2012. The diagnosis of gastrointestinal aGVHD was based on
clinical criteria according to National Institutes of Health guidelines [20] and
was conﬁrmed both endoscopically and histologically for most patients.
Steroid-refractory aGVHD was deﬁned by worsening under 2 mg/kg/day of
prednisolone over at least 4 days or by no improvements in grades III to IV
aGVHD after at least 14 days of prednisone therapy (2 mg/kg/day). Gastro-
intestinal GVHDwas considered as being acute if acute and profuse diarrhea
and abdominal pain were clinically conﬁrmed, independently of the time
interval after hematopoietic stem cell transplantation [21].
Treatment Schedule
All patients signed a written consent for data collection and analysis
concerning all the complications linked to the graft procedure. After giving
oral approval, patients received a ﬁrst dose of 30 mg alemtuzumab intra-
venously. Patients who did not show any improvement of aGVHD symptoms
in the ﬁrst 2 weeks after the injection were given 2 subsequent injections
(with a 2-week interval between each injection).
To improve the tolerance of alemtuzumab, all patients were pre-
medicated by injection of 1 g paracetamol and 1mg/kg methylprednisolone.
Methylprednisolone used for the ﬁrst-line therapy was slowly tapered off
after alemtuzumab injection, and other immunosuppressive drugs were
stopped.
Evaluation of Response, Toxicities, and Infections
Responsewas evaluated clinically by daily staging and grading of aGVHD
from the ﬁrst day of alemtuzumab treatment onward. Complete response
was deﬁned as the full resolution of rectal bleeding, abdominal pain, and
diarrheawithout the use of an antimotility agent and/or antalgics. Persistent
aGVHD was diagnosed when clinical symptoms remained unchanged or
worsened. We considered the response to be partial when there was a
Table 1
Patients Characteristic
Patient
Identiﬁcation
Number
Gender Age at
Transplant
(yr)
Disease Donor
Type
Mismatch Graft
Source
aGVHD
Grade
Stage of GI
aGVHD
Stage
of Liver
aGVHD
Treatment Before
Alemtuzumab
(Including
Steroids)
Overall
GVHD
Response
OS (d) Viral
Complication
Cause of Death
391075 F 60 AML MMD A-allele PBSCs 4 4 2 anti-TNF CR 251 EBV reactivation GVH with multiorgan failure
98059861 M 43 AML MMD C-allele PBSCs 4 4 0 anti-TNF NR 78 GVH with multiorgan failure
412050 F 41 AML MUD PBSCs 4 4 3 tacroþevrl,
anti-TNF, EPC
NR 2 CMV reactivation GVH with multiorgan failure
93023633 M 55 ML MUD PBSCs 4 4 0 tacroþevrl,
anti-TNF
CR 516 Pneumopathy with severe
hypoxemia
424542 F 22 MDS SIB PBSCs 4 4 0 tacroþevrl,
anti-TNF
NR 18 GVH with multiorgan failure
609479 M 23 ALL MUD PBSCs 4 4 0 tacroþevrl,
anti-TNF
NR 11 EBV reactivation GVH with multiorgan failure
390519 M 56 FL SIB PBSCs 4 4 1 tacroþevrl,
anti-TNF
NR 27 GVH with multiorgan failure
362942 F 51 MM MUD BM 4 4 0 tacroþevrl,
anti-TNF, MTX
CR 1076 Alive
605704 F 52 AML SIB PBSCs 3 3 0 tacroþevrl CR 1233 CMV reactivation Alive
97038870 M 55 CLL MUD PBSCs 4 4 0 Evrl CR 235 GVH with multiorgan
failureþ
infection
618602 M 41 ALL SIB BM 3 2 0 Evrl CR 1006 EBV reactivation Alive
360934 M 58 MDS MUD PBSCs 4 4 0 Evrl CR 971 Alive
641362 F 53 AML MUD PBSCs 4 4 0 NR 189 CMV reactivation GVH with multiorgan failure
643027 M 48 AML MMD C-allele PBSCs 4 4 2 NR 6 EBV reactivation GVH with multiorgan failure
385311 M 62 ML SIB PBSCs 4 4 0 NR 39 EBV reactivation GVH with multiorgan failure
169506 M 59 ML MUD PBSCs 4 4 0 CR 637 CMV reactivation Alive
684128 M 60 AML MUD PBSCs 4 4 0 CR 310 CMV reactivation uncontrolled PTLD
95050077 M 46 CLL MUD PBSCs 4 4 0 PR 477 CMV reactivation Alive
163593 M 62 MM MUD PBSCs 4 4 3 tacro PR 95 Sepsis choc
364740 M 63 MDS MUD PBSCs 3 3 0 PR 155 CMV reactivation GVH with multiorgan failure
167502 M 52 AML SIB PBSCs 3 3 1 CR 447 Alive
307119 M 48 MM MUD PBSCs 4 4 0 NR 78 CMV reactivation GVH with multiorgan failure
686434 M 59 AML MMD A-allele PBSCs 3 3 0 CR 129 CMV reactivation
PTLD
GVH with multiorgan failure
98041938 F 67 ATL MUD PBSCs 4 4 0 PR 69 GVH with multiorgan failure
GI indicates gastrointestinal; AML, acute myeloid leukemia; MMD, mismatched donor; PBSCs, peripheral blood stem cells; CR, complete response; NR, nonresponse; MUD, matched unrelated donor; tacro, tacrolimus; evrl,
everolimus; EPC, extracorporeal photopheresis; ML, marginal lymphoma;MDS,myelodysplastic syndrome;MTX,methotrexate; SIB, sibling donor; ALL, acute lymphoblatsic leukemia; FL, follicular lymphoma; BM, bonemarrow;
MM, multiple myeloma; PR, partial response; CLL, chronic lymphocytic leukemia; PTLD, post-transplant lymphoproliferative disorder; ATL, angioimmunoblastic T cell lymphoma.
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Figure 1. OS: Dashed lines represent pointwise 95% conﬁdence intervals, and
bars denote censored observations.
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for complete response were met.
After alemtuzumab injection, all patients were monitored for cyto-
megalovirus (CMV) and Epstein-Barr virus (EBV) by blood PCR twice aweek.
The same process was used for the galactomanan antigen. Blood cultures
were systematically performed 3 times a week, and some extra tests were
realized in case of fever.
Statistics
The main endpoint was overall survival (OS). Secondary endpoints
included response rate, cumulative incidence of fungal, bacterial or viral
infection and tolerance to alemtuzumab injections. OS was measured from
the ﬁrst injection of alemtuzumab until death, censoring at the date of last
follow-up. Survival life tables were established with the Kaplan-Meier
method, with median follow-up determined according to Korn [22]. The
cumulative incidences of fungal, bacterial, or viral infection were analyzed
separately, considering death as a competing risk. Statistical analyses were
performed with R 2.14.1 (http://cran.r-project.org/bin/windows/base/old/
2.14.1).
RESULTS
Twenty-four patients received alemtuzumab as the
treatment for steroid-refractory gastrointestinal aGVHD, 17
men (71%) and 7 women (29%), with a median age of
51.5 years (range, 22 to 67). All patients had undergone
allogeneic hematopoietic cell transplantation for hemato-
logic malignancies. There were 11 acute leukemias, 3 multi-
ple myelomas, 3 myelodysplastic syndromes, 3 mantle
lymphomas, 2 chronic lymphocytic leukemias, 1 follicular
lymphoma, and 1 angioimmunoblastic lymphoma.
Concerning the transplants, there were 22 peripheral
blood stem cell transplants and 2 bone marrow transplants,
from matched sibling (n ¼ 6), unrelated matched (n ¼ 14),
andmismatched donors (n¼ 4). Conditioning regimenswere
fully myeloablative for 6 patients and reduced intensity for
18 others. All patients received cyclosporine with myco-
phenolic acid for GVHD prophylaxis (Table 1).
The median time interval from transplant to gastroin-
testinal aGVHD was 97 days (range, 8 to 192). Seventeen
aGVHD cases were conﬁrmed by histological examinations.
Nineteen patients had stage 4 gastrointestinal aGVHD, 4 had
stage 3, and 1 had stage 2. Most patients had a grade IV
aGVHD (n ¼ 19), and 7 patients had acute liver aGVHD.
Alemtuzumab injection was the second-line therapy
against aGVHD for 11 patients (45.8%), the third line for 7
patients (29%), the fourth line for 4 patients (16.6%), and the
ﬁfth line for 2 patients. Eighteen patients received 2 in-
jections, 3 patients (8.6%) received 1 injection, and 3 others
received 3 injections. The median dose of alemtuzumab was
60 mg (range, 30 to 90).
After receiving alemtuzumab, 15 patients (62.4%)
responded, 11 (45.8%) showing complete response and 4
(16.6%) a partial response. Nine patients (37.6%) did not
respond. Two patients died during the ﬁrst week after the
injection and were considered as nonresponders. Seven
others died from aGVHD and multiorgan failure within an
average period of 42 days. The median time from alemtu-
zumab injection to response was 48.4 days (range, 7 to 90)
for the responding patients.
Median follow-up was 30.4 months (range, 14.9 to 41.1).
The OS estimate at 1 year for all 24 patients was 33.3% (95%
conﬁdence interval, 15.9% to 51.9%) (Figure 1). The OS esti-
mate of the 15 responding patients at 1 year was 53.3% (95%
conﬁdence interval, 26.3% to 74.4%), with 2 of these 15 pa-
tients dying from infection, 5 from recurrent GVHD, and 1
from liver post-transplant lymphoproliferative disorder.
Regarding infections, for patients who responded posi-
tively, there were 6 reactivations of CMV, and all patientsneeded antiviral treatment, but there was no CMV disease.
The average time from alemtuzumab’s injection to CMV
reactivation to was 39 days (range, 11 to 121). There were 2
cases of EBV reactivation: 1 did not need any treatment
because a spontaneous decrease in the viral load was
observed and the other developed a liver post-transplant
lymphoproliferative disorder (EBV þ diffuse large B-cell
lymphoma [DLBCL]). These results translate into cumulative
incidences of viral infection of 41.6% and 51.8% at 12 and
24 months, respectively (Figure 2). One patient presented a
probable pulmonary aspergillosis infection.
Alemtuzumab was fairly well tolerated. Nevertheless, fe-
ver, nausea, and tingles were observed in 3 patients despite
the premedication. One patient experienced a transitory
coronary spasm with elevation of troponin and transient
electrocardiographic modiﬁcation with ST depression in the
inferior territory.
DISCUSSION
We report a single-center experience of alemtuzumab
treatment for steroid-refractory aGVHD or aGVHD resistant
to another line of immunosuppressive drug after steroids. A
partial responseecomplete response rate of 62.4% was
observed after an average time of 48.4 days. In comparison,
Schnitzler et al. [23] found an overall response rate of 70%,
with a complete response rate of 35% for treatment of 20
patients with steroid-refractory grades III and IV intestinal
GVHD. Patients received 10 mg alemtuzumab intravenously,
and the treatment was repeated weekly until the symptoms
disappeared. The median dose of alemtuzumab was 27 mg
(range, 10 to 50).
Schub et al. [24] treated 18 aGVHD patients with an
average dose of 95.5 mg alemtuzumab and reported 94.4% of
patients to be responders, but with a high rate of opportunist
infections. We found similar results, but for 12 patients (50%)
alemtuzumab was not the second line of treatment, and
these patients had a very refractory disease with multiple
previous lines of immunosuppressive drugs. One study [25]
provided some results on the use of alemtuzumab as the
third line of treatment for refractory aGVHD. Thirteen pa-
tients presenting aGVHD of the skin or gastrointestinal tract
were treated by 10 mg s.c. for 5 days in a row, and the overall
Figure 2. Cumulative viral reactivation rate after the ﬁrst alemtuzumab
injection.
M. Meunier et al. / Biol Blood Marrow Transplant 20 (2014) 1435e14541454response rate was 23%. These results highlight the fact that
alemtuzumab is an efﬁcient option against corticoid-
refractory gastrointestinal aGVHD with a relatively low
infection rate (this is approximately the same rate as that
observed for other immunosuppressive drugs [26]).
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